Almirall, LLC, a global biopharmaceutical company focused on skin health, announced its microtubule inhibitor ointment, KLISYRI® (tirbanibulin), a...
- The UK and Germany are the first two European countries where Klisyri® will be available for prescription. The product has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Commission
Almirall`s Klisyri (tirbanibulin) Receives Approval in Europe
BARCELONA, Spain, May 21, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the regulatory approval of Klisyri® (tirbanibulin), indicated for the topical treatment of actinic keratosis (AK) on the face or scalp.
EXTON, Pa., Feb. 18, 2021 /PRNewswire/ -- Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on skin health, announced today the U.S. commercial launch of Klisyri® (tirbanibulin), developed for the topical treatment of actinic keratosis (AK) of the face and scalp. Klisyri® was approved by the U.S. Food and Drug Administration (FDA) in December 2020 and is now commercially available.
BUFFALO, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the New England Journal of Medicine (NEJM) has published the results from the pivotal Phase III trials of Klisyri® ointment for actinic keratosis of the face or scalp in the February 11, 2021, issue.